Type2 Diabetes, Heart Failure
Conditions
Brief summary
It is a mechanistic proof-of-concept study to demonstrate how SGLT-2 inhibitors (Canagliflozin) may have a beneficial role on cardiac energetic efficiency. Patients with type 2 diabetes and with HF diagnosed for at least 3 months will be selected. The participants will be randomized to a double-blind, crossover 2-week placebo vs. Cana 100 mg once daily, an interventional trial with a one-month washout period in between. At the term of the two-week placebo and canagliflozin treatment periods (visits 2 and 4), each participant will undergo an identical postprandial metabolic study with positron emission tomography (PET) and stable isotopic tracer methods.
Detailed description
Non-invasive Positron Emission Tomography (PET) imaging method allows to measure myocardial uptake and organ-specific partitioning of dietary fatty acids (DFA). It allows to study kidney, liver, skeletal muscles and adipose tissues DFA utilization, whole body fatty acid turnover and oxidation rates, myocardial oxidative metabolism and left ventricular (LV) function that are other likely targets of SGLT-2 inhibitors. Thus, the PET is ideal to verify the very interesting hypothesis that, increase in liver fatty acid utilization and/or adipose tissue dietary fatty acid uptake, may lead to reduced cardiac utilization of fatty acids and improved cardiac energetic efficiency. .
Interventions
2-week intervention
DRUGPlacebo oral capsule
2-week intervention
RADIATIONPET imaging
1 day postprandial metabolic protocol at the end of treatment: CT scan followed by dynamic and pancorporel imaging
Sponsors
Janssen Inc.
Université de Sherbrooke
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)
Intervention model description
Placebo-controlled, double-blind, randomized crossover 2-week intervention study.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* HbA1c 7.5 -10.5%; * LVEF \< 40%; * NYHA class 2 or 3; * NT pro-BNP level \> 600 pg/mL; * Being on a stable-dose metformin therapy max 2500 mg/day or other hypoglycemic therapy and RAAS-blocking agents for at least 8 weeks; * Being on optimal and stable-doses of heart failure medication including diuretics for at least 4 weeks;
Exclusion criteria
* age \<18 yo; * NYHA class 4; * Treatment with a fibrate or thiazolidinedione; * Unstable or advanced renal failure; * Unstable or new medical or surgical condition within the past 3 months; * Heart failure caused by active inflammatory condition such as sarcoidosis or any form of myocarditis; * History of diabetic ketoacidosis; * Not on a stable regimen for at least 8 weeks before the screening visit; * Female of child-bearing potential who is pregnant, breast feeding or intends to become pregnant or pre-menopausal female with a positive serum pregnancy test at the time of enrollment; * Patients post bariatric surgery, or on weight loss medication; * Contraindications to metformin, including allergy or intolerance; * Hospitalization for heart failure within the 60 days prior to enrollment; * Admission for an acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery within the 60 days prior to enrollment; * Planned cardiovascular revascularization (percutaneous intervention or surgical) or major cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular assist device, cardiac transplantation, or any other surgery requiring thoracotomy) within the 90 days after enrollment; * Patients who are volume depleted based upon physical examination at the time of enrollment; * Chronic disabling illness; * History of substance abuse.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change to be observed with canagliflozin on myocardial dietary fatty acid uptake | 3 months | will be assessed using oral administration of 18-fluoro-thiaheptadecanoic acid (\[18F\]-FTHA) with sequential dynamic. PET/CT scanning. |
| Change to be observed with canagliflozin on whole-body partitioning. | 3 months | will be assessed using oral administration of 18-fluoro-thiaheptadecanoic acid (\[18F\]-FTHA, with static PET/CT scanning |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| myocardial and liver NEFA uptake | 3 months | using PET with \[11C\]-palmitate |
| NEFA oxidative rate | 3 months | using PET with \[11C\]-acetate |
| plasma NEFA turnover | 1 year | using i.v. infusion of \[U-13C\]-palmitate |
Other
| Measure | Time frame | Description |
|---|---|---|
| hormonal response | 1 year | will be determined using a multiplex assay system |
| β-cell function | 1 year | will be assessed by calculation of the disposition index (DI) that is insulin secretion in response to the ambient insulin |
| Biomarkers | 1 year | Assays will be performed using the BIOPLEX |
| body composition | 3 months | DXA |
| Insulin sensitivity | 1 year | will be determined using the HOMA-IR (based on fasting insulin and glucose levels) |
| Insulin secretion rate | 1 year | will be assessed using deconvolution of plasma C-peptide with standard Cpeptide kinetic parameters |
Outcome results
None listed